Affiliate Disclosure: This content contains affiliate links to health providers and services. BestMedsHub may receive compensation when you click through and take action. This compensation may impact how and where products and providers appear on this site. BestMedsHub does not include all providers or products available in the marketplace. This information is not medical advice — always consult a qualified healthcare professional.
Talkspace diagnoses ADHD and treats it with non-stimulant medication and therapy – it does not prescribe Adderall, Vyvanse, or any other controlled substance, at any price, in any state. That is not a fine-print catch buried in a terms-of-service page; it is the entire premise of this listing. Talkspace is the deliberately labeled non-stimulant option in our ADHD roster, and if you arrive expecting a stimulant prescription, you will leave disappointed. We are telling you on line one so the platform does not have to tell you after you have paid for an evaluation.
So why include it at all? Because non-stimulant medication is a legitimate, evidence-supported ADHD treatment path, not a consolation prize, and because Talkspace pairs it with two things most ADHD telehealth startups cannot match: in-network coverage with most major insurance plans and genuine therapy integration on the same platform. For a meaningful slice of people with ADHD, that combination is exactly right. For everyone else, we link you to the providers that can prescribe stimulants further down this review.
Regulatory note (verified June 2026): As of June 2026, DEA-registered telehealth providers can legally prescribe ADHD medications – including Schedule II stimulants like Adderall and Vyvanse – without a prior in-person visit, under temporary federal flexibilities extended through December 31, 2026. A permanent DEA rule is pending, and state laws and individual platform policies may be stricter. Talkspace’s own policy is stricter than federal law allows: it does not prescribe controlled substances at all.
Key takeaways
- Talkspace can evaluate and diagnose ADHD, provide therapy, and prescribe non-stimulant ADHD medication such as atomoxetine (the Strattera class).
- It will not prescribe Adderall, Vyvanse, or any controlled substance. This is platform policy, not a temporary regulatory limitation.
- It is in-network with most major insurance plans; Talkspace’s own marketing cites a $15 average copay. Cash psychiatry starts at roughly $299 for an initial evaluation.
- Trustpilot rating sits at 4.4/5 as of June 2026, with a notably polarized split between 1-star and 5-star reviews.
- If the evaluation indicates that stimulant medication is the right treatment, Talkspace refers you out rather than prescribing it.
What is Talkspace?
Talkspace, Inc. is a publicly traded telehealth mental health company (NASDAQ: TALK) founded in 2012 and headquartered in New York City. It operates one of the largest online therapy and psychiatry networks in the United States, and unlike most of the ADHD-specific platforms in this roster, it is in-network with insurance at real scale. You can read its service terms directly at talkspace.com.
ADHD care at Talkspace sits inside its general psychiatry service rather than a dedicated ADHD funnel. That cuts both ways. You get a full psychiatric evaluation from a licensed prescriber who can also assess the anxiety, depression, and sleep problems that frequently travel with ADHD. What you do not get is a prescriber who can write for the most commonly prescribed ADHD medications, because Talkspace prescribes psychiatric medications with one bright-line exception: no controlled substances, ever. For ADHD, that means non-stimulants only.
Who non-stimulant ADHD treatment actually fits
Let’s be clinically honest in both directions. Stimulants produce larger average symptom reductions in head-to-head research, which is why they are the default first prescription for most adults with ADHD, and any review that pretends otherwise is not being straight with you. Non-stimulants such as atomoxetine also typically take longer to reach full effect than a stimulant does.
But non-stimulant medication is a first-line choice, not a fallback, for several real groups of patients: people with medical contraindications to stimulants, people in addiction recovery who have decided controlled substances are off the table, people whose past stimulant trials produced intolerable side effects, and people who simply prefer not to take a Schedule II medication. For these patients, a platform that structurally cannot prescribe stimulants is not a limitation; it is a feature. There is no monthly controlled-substance refill friction, no pharmacy stocking lottery, and no ambiguity about what the prescriber’s incentives are. Add therapy on the same platform, where skills-based work has its own evidence base for adult ADHD, and the package is coherent rather than compromised.
How ADHD care works at Talkspace
- Intake and matching. You complete an intake questionnaire and are matched with a licensed prescriber in your state, with the option to add a therapist.
- Psychiatric evaluation. The initial appointment is a full psychiatric evaluation that can include ADHD assessment and formal diagnosis, along with screening for co-occurring conditions.
- Treatment plan. If ADHD is diagnosed, treatment can include therapy, non-stimulant medication from the atomoxetine/Strattera class, or both, with follow-up medication management visits.
- Referral out if stimulants are indicated. If your prescriber concludes that stimulant medication is the appropriate treatment, Talkspace does not write the prescription. You are referred to outside care, and you start the evaluation process again elsewhere.
That fourth step is the one to sit with before you sign up. If you already suspect you will need a stimulant, beginning at Talkspace means potentially paying for an evaluation that ends in a referral rather than a prescription.
Pricing and insurance
Insurance is Talkspace’s strongest card. It is in-network with most major plans, and the company’s own marketing cites a $15 average copay; treat that as Talkspace’s claim rather than a promise about your specific plan, and verify your benefits before booking. Without insurance, psychiatry starts at roughly $299 for the initial evaluation, which is on the expensive end of this roster for cash-pay patients.
| Service | What you get | Cost (June 2026) |
|---|---|---|
| In-network psychiatry | Evaluation, diagnosis, and non-stimulant medication management billed through insurance | Copay set by your plan; Talkspace cites a $15 average |
| Cash-pay psychiatry | Initial psychiatric evaluation without insurance | From about $299 |
| Stimulant prescriptions (Adderall, Vyvanse, etc.) | Not offered | Not available at any price |
Reputation and complaints
As of June 2026, Talkspace holds a 4.4/5 rating on Trustpilot. That headline number deserves a caveat: the distribution is polarized, with a visible split between 5-star reviews praising therapist quality and insurance coverage and 1-star reviews citing billing disputes and clinician mismatches. A 4.4 built on extremes is a different signal than a 4.4 built on consistency, so read a page of each before deciding.
The ADHD-specific complaint pattern is the one this entire review is built around: people sign up expecting stimulant medication, complete an evaluation, and only then learn that Talkspace will not prescribe it. That is a genuine and recurring source of frustration, and it is avoidable with one sentence of disclosure, which is why we put that sentence first.
On the prescribing side, the record is clean. Talkspace has never prescribed controlled substances, which means it has no exposure to the DEA scrutiny and overprescribing controversies that have followed some stimulant-prescribing telehealth startups in recent years. There is no regulatory action on its prescribing practices to report. For a risk-averse patient, that is worth something.
Who Talkspace is best for
- People who want non-stimulant ADHD treatment by choice, contraindication, or recovery history
- Patients who want to use in-network insurance rather than pay cash subscription fees
- Anyone who wants therapy and medication management on one platform, especially with co-occurring anxiety or depression
- People who specifically want to avoid controlled substances and the refill logistics that come with them
Who should look elsewhere
- Anyone set on stimulant treatment, or whose prior care history suggests stimulants are likely to be indicated; start with a platform that can actually prescribe them and compare ADHD telehealth providers before paying for any evaluation
- Cash-pay patients on a budget, since the roughly $299 initial evaluation is high without insurance
- People who want an ADHD-specialized clinic rather than ADHD care inside a general psychiatry service
If you are unsure where stimulant prescribing currently stands across the industry, our guide to which platforms can prescribe stimulants covers the June 2026 landscape, including the temporary federal flexibilities and the platforms whose policies are stricter than the law requires.
Final verdict
Talkspace earns its 8.4 editorial score by being excellent at a narrower job than most shoppers assume it does. As an insurance-friendly platform for ADHD diagnosis, therapy, and non-stimulant medication, it is arguably the strongest option in this roster, backed by a 2012-founded public company with a clean prescribing record. As a route to Adderall or Vyvanse, it is a dead end by design. Know which patient you are before you book, and Talkspace is either exactly right or entirely wrong for you; there is very little in between.